ScoreWhy is Kymera Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -239.31% of over the last 5 years
2
The company has declared negative results for the last 3 consecutive quarters
- The company has declared negative results in Sep 24 after 3 consecutive negative quarters
- INTEREST(HY) At USD 0.21 MM has Grown at 70.25%
- OPERATING CASH FLOW(Y) Lowest at USD -227.92 MM
- DEBT-EQUITY RATIO (HY) Highest at -44.56 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 136.51%, its profits have fallen by -79.2%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -3.23% over the previous quarter and currently hold 16.63% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Kymera Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Kymera Therapeutics, Inc.
120.83%
1.52
81.95%
S&P 500
13.68%
0.84
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.63%
EBIT Growth (5y)
-239.31%
EBIT to Interest (avg)
-158.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.87
EV to EBIT
-18.29
EV to EBITDA
-18.76
EV to Capital Employed
13.22
EV to Sales
137.35
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-72.28%
ROE (Latest)
-30.78%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -154.93 MM
CASH AND EQV(HY)
Highest at USD 1,171.13 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 66.41 times
-30What is not working for the Company
INTEREST(HY)
At USD 0.21 MM has Grown at 70.25%
OPERATING CASH FLOW(Y)
Lowest at USD -227.92 MM
DEBT-EQUITY RATIO
(HY)
Highest at -44.56 %
RAW MATERIAL COST(Y)
Grown by 53.34% (YoY
NET SALES(Q)
Lowest at USD 2.76 MM
OPERATING PROFIT(Q)
Lowest at USD -86.52 MM
OPERATING PROFIT MARGIN(Q)
Lowest at -3,130.14 %
PRE-TAX PROFIT(Q)
Lowest at USD -78.32 MM
NET PROFIT(Q)
Lowest at USD -78.32 MM
Here's what is working for Kymera Therapeutics, Inc.
Cash and Eqv
Highest at USD 1,171.13 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 66.41 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Depreciation
Highest at USD 2.15 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Kymera Therapeutics, Inc.
Net Sales
At USD 2.76 MM has Fallen at -75.27%
over average net sales of the previous four periods of USD 11.18 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Interest
At USD 0.21 MM has Grown at 70.25%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -44.56 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Operating Cash Flow
Lowest at USD -227.92 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Net Sales
Lowest at USD 2.76 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Operating Profit
Lowest at USD -86.52 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Operating Profit Margin
Lowest at -3,130.14 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at USD -78.32 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -78.32 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Raw Material Cost
Grown by 53.34% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
